{"title":"Impact of response on survival according to type of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer.","authors":"Tetsuo Shimizu, Masayuki Nomoto, Yoshiko Nakagawa, Yasuhiro Gon","doi":"10.1080/1120009X.2025.2524914","DOIUrl":null,"url":null,"abstract":"<p><p>Response is a surrogate marker of survival used to determine the efficacy of cancer chemotherapy. However, it is unclear whether the impact of the response on survival depends on the ICI type. This study aimed to assess whether the impact of response on survival differed by the ICI type. We conducted a study on 137 patients who received ICIs (pembrolizumab or atezolizumab) plus chemotherapy for chemotherapy-naïve advanced NSCLC. We analyzed the association between response and survival for each type of ICIs. In the response group, the pembrolizumab-based regimen had significantly more prolonged PFS than the atezolizumab-based regimen (48.1 vs. 8.6 months, P < 0.01). OS was also significantly different between the two groups (Not reached vs. 32.5 months, P = 0.04). Multivariate analysis showed that the pembrolizumab regimen reduced the risk of disease progression by 63% compared to the atezolizumab regimen. The impact of the response on survival differs according to the ICI type.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-9"},"PeriodicalIF":1.9000,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1120009X.2025.2524914","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Response is a surrogate marker of survival used to determine the efficacy of cancer chemotherapy. However, it is unclear whether the impact of the response on survival depends on the ICI type. This study aimed to assess whether the impact of response on survival differed by the ICI type. We conducted a study on 137 patients who received ICIs (pembrolizumab or atezolizumab) plus chemotherapy for chemotherapy-naïve advanced NSCLC. We analyzed the association between response and survival for each type of ICIs. In the response group, the pembrolizumab-based regimen had significantly more prolonged PFS than the atezolizumab-based regimen (48.1 vs. 8.6 months, P < 0.01). OS was also significantly different between the two groups (Not reached vs. 32.5 months, P = 0.04). Multivariate analysis showed that the pembrolizumab regimen reduced the risk of disease progression by 63% compared to the atezolizumab regimen. The impact of the response on survival differs according to the ICI type.
期刊介绍：
The Journal of Chemotherapy is an international multidisciplinary journal committed to the rapid publication of high quality, peer-reviewed, original research on all aspects of antimicrobial and antitumor chemotherapy.
The Journal publishes original experimental and clinical research articles, state-of-the-art reviews, brief communications and letters on all aspects of chemotherapy, providing coverage of the pathogenesis, diagnosis, treatment, and control of infection, as well as the use of anticancer and immunomodulating drugs.
Specific areas of focus include, but are not limited to:
· Antibacterial, antiviral, antifungal, antiparasitic, and antiprotozoal agents;
· Anticancer classical and targeted chemotherapeutic agents, biological agents, hormonal drugs, immunomodulatory drugs, cell therapy and gene therapy;
· Pharmacokinetic and pharmacodynamic properties of antimicrobial and anticancer agents;
· The efficacy, safety and toxicology profiles of antimicrobial and anticancer drugs;
· Drug interactions in single or combined applications;
· Drug resistance to antimicrobial and anticancer drugs;
· Research and development of novel antimicrobial and anticancer drugs, including preclinical, translational and clinical research;
· Biomarkers of sensitivity and/or resistance for antimicrobial and anticancer drugs;
· Pharmacogenetics and pharmacogenomics;
· Precision medicine in infectious disease therapy and in cancer therapy;
· Pharmacoeconomics of antimicrobial and anticancer therapies and the implications to patients, health services, and the pharmaceutical industry.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
